CYP2C19 and myocardial infarction: Genetic variants in CYP2C19 impair function with subsequently reduced Clopidogrel active plasma levels [14], and we have previously shown using primary care linked data on UK Biobank participants that carriers of these variants have increased risks of ischemic stroke and myocardial infarction (MI) whilst prescribed Clopidogrel [7].